Method and system for the analysis and association of patient-specific and population-based genomic data with drug safety adverse event data

Abstract

A method for assessing and analyzing one or more drugs, adverse effects and associated risks, and patient characteristics resulting from the use of at least drug of interest is disclosed. The method comprises the steps of selecting one or more cases for analysis, said cases describing the behavior between at least one drug of interest and a patient genotype; profiling statistically derived values from multiple cases related to the safety of the at least one drug, wherein at least one filter is employed for deriving said values; at least one data mining engine; and an output device for displaying the analytic results from the data mining engine. A system for performing the method is likewise disclosed.

Description

RELATED APPLICATIONS[0001]This application is a continuation application of U.S. Ser. No. 10 / 229,119, filed Aug. 28, 2002, which claims the benefit of U.S. Provisional Application No. 60 / 315,525, filed Aug. 29, 2001, and is related to each of the following applications: U.S. patent application Ser. No. 09 / 681,586, filed May 2, 2001; U.S. patent application Ser. No. 09 / 681,587, filed May 2, 2001; U.S. patent application Ser. No. 09 / 681,583, filed May 2, 2001; and U.S. patent application Ser. No. 09 / 845,722, filed May 2, 2001, the disclosures of which are incorporated herein by reference in their entireties.TECHNICAL FIELD[0002]The present invention relates to a drug safety database. More particularly, the invention relates to a method and system for creating and utilizing a database that relates drugs, adverse events, patient characteristics, and in particular, genetic information.BACKGROUND OF THE INVENTION[0003]Publicly and privately developed pharmacological data is readily availa...

AI Technical Summary

Benefits of technology

[0012]The system described herein is in the area of genomic drug safety, and accordingly provides a method to evaluate existing and / or potential drugs from a genomic point of view. This method takes the drug dimension, with its different characteristics (e.g. chemical class) and adds information regarding the metabolic pathway of drugs (including current and historical drugs), thereby creating genetically relevant taxonomies of drugs. The method also includes demographic information such as the phenotype and genotype of a particular patient involved with a particular reaction (case). These extensions allow the resulting application to correlate drugs with the metabolizing characteristics of specific patient genotypes. As such, the method shows how these drug / genotype interactions lead to increased or decreased chances for particular adverse reactions.

[0014]In accordance with the method, data is collected, for example, from a multitude of sources, and is then analyzed and stored in a standardized data structure. A method of developing “mappings” allows data to be consistently compared and analyzed even if the original sources use incompatible language.

[0017]Since it is possible to check all combinations of genotypes against all drug information, an additional benefit of the present invention is the capability to prepare a database of known relationships and apply them prior to or at the point-of-care (POC). This allows the physician to check a particular patient profile against the drug to be prescribed to assess the risk of an adverse drug reaction for that patient.

Problems solved by technology

Whereas drugs generally metabolize in one or two pathways, adverse events can occur in any of the body systems or pathways, even those not originally believed to be impacted by the drug, leading to extreme complexity.

Images